Patients starting chloroquine (CQ) or hydroxychloroquine (HCQ; i.e. Plaquenil) should have a baseline examination that serves as a reference point, as well as to rule out any preexisting maculopathies. Hydroxychloroquine 200 mg dosage Medication similar to plaquenil Side effects from stopping plaquenil Chloroquine maculopathy ppt Plaquenil is commonly used in rheumatoid arthritis, but was originally developed as an antimalarial medication. A number of immunodeficient conditions may be treated with Plaquenil, including Sjögren’s syndrome, a number of autoimmune diseases such as lupus and Coxiella burnetii-related heart infections. 4-6 Aug 06, 2014 Hydroxychloroquine, sold under the brand name Plaquenil Sanofi-Aventis, is an antimalarial drug that has gained widespread use in treating various autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis. 1 By some estimates, more than 150,000 patients are on long-term therapy with this medication in America alone. 2 Retinal toxicity associated with HCQ use is. Published April 20, 2011 New Plaquenil Guidelines Here is a look at the 2011 testing guidelines for patients on Plaquenil guidelines. Diana L. Shechtman, O. D. and Paul M. Karpecki, O. D. Background: The American Academy of Ophthalmology recommendations on screening for chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. While most rheumatologists are now routinely prescribing their patients 400 mg of HCQ (or 250 mg CQ) daily for the management of conditions like systemic lupus erythematosus and rheumatoid arthritis, individuals of short stature often have their dosage determined off of their ideal body weight to avoid overdosing. Plaquenil guidelines review of optometry Coding Eye Exam For Plaquenil, Multimodal Imaging in Plaquenil Toxicity Does plaquenil ease symptoms of ms and als AAO Screening Guidelines for Plaquenil. Check out my recent review/summary of the American Academy of Ophthalmology’s statement on the Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy 2016 Revision from the Ophthalmology Journal 2016;186-1394. AAO Screening Guidelines for Plaquenil. New Plaquenil Guidelines -. Recommendations on Screening for Chloroquine and.. Plaquenil hydroxychloroquine is in a class of drugs called disease-modifying anti-rheumatic drugs, which are used to decrease inflammation, pain and joint damage. While today it is used to treat autoimmune conditions, such as rheumatoid arthritis and lupus, it was originally used as an anti-malaria drug. Plaquenil, widely used to treat lupus, rheumatoid arthritis and other inflammatory and dermatologic conditions, is very effective, and “the risk of toxicity in the first five years for someone without special risk factors is very low,” Dr. Marmor said. However, risk increases with duration of use. The traditional protocol for following patients on Plaquenil therapy consisted of baseline photography as well as annual color vision testing, Amsler grid and 10-2 visual fields annually. 2,3 Under the new guidelines, color vision and Amsler grid testing are no longer considered acceptable screening methods so they have been removed from the protocol. 2,3 However, 10-2 visual fields are still important.